The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ZEPZELCA (Specialised Therapeutics Pharma Pty Ltd)
Product name
ZEPZELCA
Date registered
Evaluation commenced
Decision date
Approval time
153 (255 working days)
Active ingredients
lurbinectedin
Registration type
NCE/NBE
Indication
ZEPZELCA (powder for injection) is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed on or after prior platinum-containing therapy. This indication was approved via the provisional approval pathway, based on objective response rate and duration of response in a single arm trial. Continued approval for this indication depends on verification and description of clinical benefit in a confirmatory trial.